Evidence-informed vaccine decision making: The introduction of Human Papilloma Virus (HPV) vaccination in the Netherlands

Ingeborg M. van der Putten*, Aggie T. G. Paulus, Mickael Hiligsmann, Raymond C. W. Hutubessy, Silvia M. A. A. Evers

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

99 Downloads (Pure)


Little is known about the role of (economic) information or evidence in the different stages of the decision-making process on vaccine introduction. By conducting a document analysis on the public decision-making process of introducing human Papilloma virus (HPV) vaccine into the national vaccination program (NVP) in the Netherlands, we aim to gain insight into which information plays a role during the introduction of a vaccination programme.

A document analysis was performed on the public decision-making process regarding the introduction of HPV vaccine into the NVP in the Netherlands. Information used or asked for by various stakeholders during different stages of the policymaking process was identified. In total, 42 documents were found, analyzed and synthesized, for the period between August 2006 and September 2009. Documents were analyzed using directed content analysis based on eight broad categories of criteria used in decision-making frameworks for introducing a vaccine.

Our analysis demonstrates that a wide variety of stakeholders is involved in the process. Financial or economic issues were stipulated in 64.3% of the documents and information on vaccine characteristics were discussed in 59.5%. Economic information from economic evaluations was discussed most (47.6%). Based on our analysis, it can be concluded that economic information, in particular information from economic evaluations, played an important role in the decision-making process regarding the introduction of HPV-vaccination. (C) 2018 Elsevier B.V. All rights reserved.

Original languageEnglish
Pages (from-to)260-266
Number of pages7
JournalHealth Policy
Issue number3
Publication statusPublished - Mar 2019


  • Policy making
  • Vaccines
  • Papillomavirus vaccines
  • Costs and cost analysis
  • Immunization programs
  • Netherlands

Cite this